Clinical trials: Left Ventricle Remodeling
Left Ventricle Remodeling, Left Ventricle Dilated
RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial
A prospective, multi-center randomized trial comparing the Revivent System plus GDMT to GDMT alone. A total of approximately 135 subjects will be randomized in a 2:1 allocation ratio (90 treatment and 45 control), with…
- Conditions
- Left Ventricle Remodeling, Left Ventricle Dilated, CHF
- Trial name
- RELIVE (NCT06813820)
- Testing
- Revivent System
- Where
- 6 sites in United States
- Volunteers
- 135 people
- Sponsor
- BioVentrix
Congestive Heart Failure, Mitral Regurgitation
Speckle Tracking Imaging and Realtime 3 Dimensional Echocardiograhy to Study LV Function and Remodeling After Acute Myocardial Infarction (AMI)
Left ventricular (LV) remodeling after acute myocardial infarction (AMI) has been well described in previous studies. However, there is a paucity of data on the incidence of and risk factors for LV remodeling in modern clinical…
- Trial name
- NCT00745680
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Heart Failure, Cardiomyopathies
The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy
Heart failure affects over 5.3 million Americans and, while other cardiovascular diseases have enjoyed a reduction in mortality rates over the last decade, the mortality from heart failure continues to rise[1].
- Trial name
- NCT00696410
- Testing
- Zinc Acetate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Michigan
Acute Myocardial Infarction (AMI), PCI Patients
The Effect of Cardiac Rehabilitation on Left Ventricular Remodeling in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
Cardiac rehabilitation has proven to improve the functional capacity of patients who had acute myocardial infarction. However, its effect on Left ventricular remodeling following an MI event treated with Primary PCI is not yet…
- Conditions
- Acute Myocardial Infarction (AMI), PCI Patients, Percutaneous Coronary Intervention (PCI), Primary Percutaneous Coronary Intervention
- Trial name
- NCT07155928
- Testing
- Cardiac Rehabilitation, Primary Percutaneous Coronary Intervention
- Volunteers
- 100 people
- Sponsor
- Assiut University
AMI, STEMI
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors.
- Conditions
- AMI, STEMI, NSTEMI, Left Ventricular Dysfunction
- Trial name
- DAPAPROTECTOR (NCT05764057)
- Testing
- Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Left Ventricular Dyssynchrony, Heart Failure
AMEND-CRT: Mechanical Dyssynchrony as Selection Criterion for CRT
Previous experience with cardiac resynchronization therapy (CRT) candidates suggests that selection of these patients can be improved.
- Conditions
- Left Ventricular Dyssynchrony, Heart Failure, Cardiomyopathy, Dilated, Cardiac Remodeling, Ventricular
- Trial name
- AMEND-CRT (NCT04225520)
- Testing
- Cardiac resynchronization therapy ON, Cardiac resynchronization therapy OFF
- Where
- 24 sites in Belgium, Brazil and 9 more
- Volunteers
- 500 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Acute Coronary Syndromes
Controlled Level EVERolimus in Acute Coronary Syndromes
Acute myocardial infarction (AMI) constitutes the major cause of death in most nations and death rates and morbidity remain substantial in the years thereafter.
- Trial name
- CLEVER-ACS (NCT01529554)
- Testing
- Everolimus
- Where
- 8 sites in Germany, Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
Heart Failure, Diabetes
Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes
Patients with diabetes are at increased risk of developing heart failure (HF) which can lead to increased shortness of breath, reduced ability to exercise and in some cases premature death as the heart becomes less efficient at…
- Trial name
- REFORM (NCT02397421)
- Testing
- Dapagliflozin
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- University of Dundee
Regurgitation, Mitral
Impact of Preoperative Myocardial Fibrosis Related to Mitral Valve Prolapse on Postoperative Left Ventricular Remodeling
Primary mitral regurgitation (MR) is the most common valvular disease in western countries. The MR mechanism is often related to a mitral valve prolapse (MVP) defined as a single or bi-leaflet prolapse of at least 2 mm beyond the…
- Trial name
- IMPARED (NCT05284058)
- Testing
- Cardiac Magnetic Resonance Imaging (MRI)
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Hospices Civils de Lyon
Myocardial Infarction
BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling
This study is being done to determine the effects (good and bad) of intravenous infusion of a human brain natriuretic peptide (BNP), Natrecor (nesiritide), a hormone produced by the heart in persons who have just suffered a heart…
- Trial name
- NCT00252213
- Testing
- Human BNP
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Heart Failure, Congestive
The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure
The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure
- Trial name
- REMODEL (NCT00082589)
- Testing
- Eplerenone
- Where
- 53 sites in United States
- Volunteers
- 250 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cardiovascular Diseases
Predictive Value of Cardiovascular Magnetic Resonance Related Parameters in STEMI Patients After Primary PCI for Adverse Left Ventricular Remodeling and Major Adverse Cardiovascular Events
This study aim to investigate the predictive value of CMR parameters: infarct size (IS), intramyocardial hemorrhage, microvascular obstruction, area at risk and CMR derived strain parameters with the Major Adverse Cardiovascular…
- Trial name
- NCT04789564
- Testing
- cardiovascular magnetic resonance (CMR)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Qian geng
Heart Failure, Left Bundle-Branch Block
Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients
Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with increased mortality, more frequent hospitalization…
- Conditions
- Heart Failure, Left Bundle-Branch Block, Ischemic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy
- Trial name
- RECOVER-HF (NCT05769036)
- Testing
- Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing, Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Cardiac Remodeling
Baxdrostat and Ventricular Remodeling
The goal of this trial is to learn whether adding the blood pressure medication baxdrostat (Baxfendy) to standard-of-care medical therapies will beneficially change the heart structure and function of adults who have high blood…
- Trial name
- BaxREMODEL (NCT07655362)
- Testing
- Baxdrostat
- Where
- 2 sites in Canada
- Volunteers
- 286 people
- Sponsor
- Subodh Verma
Aortic Stenosis, Aortic Valve Stenosis
Angiotensin Receptor Blockers in Aortic Stenosis
This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.
- Trial name
- ARBAS (NCT04913870)
- Testing
- Angiotensin Receptor Blockers
- Where
- 2 sites in Canada, Denmark
- Volunteers
- 144 people
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Diabetes
Impact of Diabetes on Left Ventricular Remodeling
The investigators hypothesize that in patients with diabetes and acute myocardial infarction (MI), Ang II type-1 receptor blockade (AT1RB) attenuates left ventricle (LV) remodeling to a greater extent than angiotensin converting…
- Trial name
- P3 (NCT01052272)
- Testing
- Ramipril, Candesartan cilexetil, Allopurinol
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Alabama at Birmingham
Heart Failure
Safety and Efficacy Study of the BioVentrix PliCath HF System
The purpose of this prospective, single-armed, multi-center clinical trial is to further establish the safety and feasibility of using the BioVentrix PliCath HF System for the treatment of left ventricular dysfunction in…
- Trial name
- CONFIGURE-HF (NCT01568164)
- Testing
- PliCath HF System
- Where
- 19 sites in Austria, Czechia and 9 more
- Volunteers
- 120 people
- Sponsor
- BioVentrix
Heart Failure
Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure
Background: Sacubitril/valsartan, a novel therapy in the treatment of heart failure with reduced ejection fraction (HFrEF), has recently proved efficacy in improving exercise tolerance and cardiac performance.
- Trial name
- NCT04434170
- Testing
- Sacubitril-Valsartan
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- Centro Cardiologico Monzino
ST Elevation Myocardial Infarction (STEMI)
Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI
For patients with anterior ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), whether early application of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors to…
- Trial name
- EVALUATE-STEMI (NCT05613426)
- Testing
- Rosuvastatin 20 mg, Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]
- Where
- 6 sites in China
- Volunteers
- 119 people
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
Hypertrophy, Left Ventricular
Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure
This study will assess the efficacy of mirabegron, a new beta3-adrenergic receptor in the prevention of heart failure. This is a two armed, prospective, randomized, placebo-controlled, multi-centric european phase IIb trial with…
- Trial name
- Beta3_LVH (NCT02599480)
- Testing
- mirabegron, Echocardiography, Cardiac MRI
- Where
- 10 sites in Belgium, France and 6 more
- Volunteers
- 296 people
- Sponsor
- Jean-Luc Balligand